The HealthShares Ophthalmology ETF (Ticker: HHZ) seeks to replicate as closely as possible, before expenses, the total return performance of the HealthShares Ophthalmology Index. The index is comprised of companies engaged in the research, clinical development and/or commercialization of therapeutic agents by means of pharmaceuticals, medical devices or biomaterials for the treatment of various diseases of the eye including, but not limited to, age-related macular degeneration, dry-eye, diabetic macular edema, glaucoma, presbyopia and myopia. Companies must have a minimum market capitalization greater than $100 million and less than $15 billion for at least two of the three proceeding quarters. Stocks are equally weighted when the fund is formed and then float with the market thereafter. When the weight of an individual stock reaches 15% of the index value it is adjusted down to 10%, and when a stocks falls to 2.5% it is adjusted up to 5%. S&P is the administrator of HealthShares indexes.
